FIRST QUARTER IN BRIEF Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis The expansion cohort of the study in multiple myeloma is ongoing according to plan EVENTS AFTER THE END OF THE PERIOD Start of enrollment to the clinical phase I biodistribution study…
FIRST QUARTER IN BRIEF Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30) Active Biotech published new preclinical data highlighting the mechanisms behind the anti-tumor activity of tasquinimod in hematological malignances New preclinical data on naptumomab published EVENTS AFTER THE END OF THE PERIOD Safety and…
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01) First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07) Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9) EVENTS…
Financing completed and good progress in the projects First quarter in brief Agreement signed for manufacturing of a topical ophthalmic formulation and capsules of laquinimod for use in clinical studies Activities are ongoing according to plan in the naptumomab and tasquinimod projects Corporate Rights issue prospectus published on January 5,…
First quarter in brief Active Biotech announces new direction Patent regarding use of tasquinimod in the treatment of multiple myeloma granted in Japan Events after the end of the period Due to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the…
First quarter in brief Active Biotech’s partner NeoTX entered clinical collaboration with AstraZeneca to evaluate ANYARA (“naptumumab”) in combination with IMFINZI® (durvalumab) in the upcoming Phase Ib/II study On 1 February 2019, Active Biotech received an indicative, non-binding bid of SEK 275 M for the company’s property from the real…
First quarter in brief Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018 Patent application for tasquinimod for the treatment of multiple myeloma approved in the US Product patent for the second patent family in the SILC project granted in…
Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod…
Laquinimod· The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017· The clinical Phase 2 study ARPEGGIO for the treatment of…
Laquinimod The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016 Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 Tasquinimod Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk…
Laquinimod On January 24, the laquinimod (Nerventra®) market application received a negative opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Teva has requested a re-examination of the CHMP’s opinion. In February 2014, Teva decided not to proceed with the randomization…
Laquinimod · first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of relapsing-remitting multiple sclerosis · data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment Tasquinimod · the Phase III study is proceeding according…
* Laquinimod – submission of application for regulatory approval in the EU planned for second half of 2012 – Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN) * TASQ – a Phase I investigator-sponsored clinical trial is under way – enrolment of…
* Laquinimod – complete results from Allegro Phase III trial presented * TASQ – Active Biotech and Ipsen enter into a broad partnership for the co- development and commercialization of TASQ in uro-oncology * ANYARA – ongoing Phase III study expected to be concluded in 2012 * 57-57 – orphan drug status granted…
